Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer

Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example,...

Повний опис

Збережено в:
Бібліографічні деталі
Автор: Carsten Stephan (Ed.)
Формат: Online
Мова:Англійська
Опубліковано: MDPI - Multidisciplinary Digital Publishing Institute 2021
Предмети:
Онлайн доступ:25028
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
_version_ 1869530748653928448
author Carsten Stephan (Ed.)
author_browse Carsten Stephan (Ed.)
author_facet Carsten Stephan (Ed.)
author_sort Carsten Stephan (Ed.)
collection Directory of Open Access Books
description Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others including several biomarker-based multivariate models. In addition to three studies and two reviews regarding PHI and other markers within this Special Issue “Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer”, new immunoassays with the PCa-associated aberrant glycosylation of PSA (S2,3PSA) have been published. However, it is important to know not only the diagnosis, but also the prognosis or further prediction of this very common disease. Here, several new nucleic acid or protein-based tissue biomarkers have been described. Most studies in this Special Issue used tissue microarrays and immunohistochemistry. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, represents a new area of interest for prostate cancer. Here, a very comprehensive review presents and discusses various important and promising kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications.
format Online
id doab-20.500.12854ir-45008
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher MDPI - Multidisciplinary Digital Publishing Institute
publisherStr MDPI - Multidisciplinary Digital Publishing Institute
record_format ojs
spelling doab-20.500.12854ir-450082024-03-31T13:10:15Z Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer Carsten Stephan (Ed.) R5-920 urinary biomarkers on prostate cancer serum/plasma biomarkers multivariate models prognostic factors tissue biomarkers (nuleic acid/protein-based) thema EDItEUR::M Medicine and Nursing Prostate cancer is the most common cancer in men in the Western world. Therefore, its early diagnosis in particular, which is mainly based on serum prostate-specific antigen (PSA), has gained attention in several fields of research. New biomarkers in serum and urine have been described, for example, the prostate health index (PHI) or urinary Prostate cancer gene 3 (PCA3), or others including several biomarker-based multivariate models. In addition to three studies and two reviews regarding PHI and other markers within this Special Issue “Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer”, new immunoassays with the PCa-associated aberrant glycosylation of PSA (S2,3PSA) have been published. However, it is important to know not only the diagnosis, but also the prognosis or further prediction of this very common disease. Here, several new nucleic acid or protein-based tissue biomarkers have been described. Most studies in this Special Issue used tissue microarrays and immunohistochemistry. As already described for other types of cancer, individualized medicine, such as theranostics, a combination of diagnostics and therapeutics, represents a new area of interest for prostate cancer. Here, a very comprehensive review presents and discusses various important and promising kinds of nanoparticles, as well as imaging and therapy options, suitable for theranostic applications. 2021-02-11T11:21:45Z 2021-02-11T11:21:45Z 2018-01-10 12:43:57 2017 book 25028 9783038426332 9783038426325 https://directory.doabooks.org/handle/20.500.12854/45008 eng application/octet-stream Attribution-NonCommercial-NoDerivatives 4.0 International http://www.mdpi.com/books/pdfview/book/489 http://www.mdpi.com/books/pdfview/book/489 MDPI - Multidisciplinary Digital Publishing Institute 10.3390/books978-3-03842-633-2 10.3390/books978-3-03842-633-2 46cabcaa-dd94-4bfe-87b4-55023c1b36d0 9783038426332 9783038426325 428 open access
spellingShingle R5-920
urinary biomarkers on prostate cancer
serum/plasma biomarkers
multivariate models
prognostic factors
tissue biomarkers (nuleic acid/protein-based)
thema EDItEUR::M Medicine and Nursing
Carsten Stephan (Ed.)
Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title_full Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title_fullStr Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title_full_unstemmed Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title_short Diagnostic, Prognostic and Predictive Biomarkers in Prostate Cancer
title_sort diagnostic prognostic and predictive biomarkers in prostate cancer
topic R5-920
urinary biomarkers on prostate cancer
serum/plasma biomarkers
multivariate models
prognostic factors
tissue biomarkers (nuleic acid/protein-based)
thema EDItEUR::M Medicine and Nursing
topic_facet R5-920
urinary biomarkers on prostate cancer
serum/plasma biomarkers
multivariate models
prognostic factors
tissue biomarkers (nuleic acid/protein-based)
thema EDItEUR::M Medicine and Nursing
url 25028
work_keys_str_mv AT carstenstephaned diagnosticprognosticandpredictivebiomarkersinprostatecancer